Predictors of early relapse in transplant-eligible MM patients
Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the integrative analysis of baseline prognostic features and achievement of…
Related Articles
Targeting SLAMF6 upregulation in AML: development of a novel antibody
In this presentation, Carl Sandén, PhD, Lund University, Lund, Sweden, discusses the potential of targeting SLAMF6 as a novel mechanism to overcome immune evasion in…
Welcome! You are invited to join a webinar: Post-EHA & ICML 2025 CLL highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading CLL experts present summaries on the most significant abstracts from EHA and ICML 2025 followed by interactive panel discussions debating…
Safety & efficacy of mosunetuzumab with/without the addition of lenalidomide in frontline FL & MZL
Adam Olszewski, MD, Brown University, Providence, RI, discusses the safety and efficacy of mosunetuzumab treatment in previously untreated follicular lymphoma (FL) and marginal zone lymphoma…
ICML 2025 | VJHemOnc
The 18th International Conference on Malignant Lymphoma (18-ICML) took place in Lugano, Switzerland, on 17-21 June, 2025. This meeting brought together lymphoma experts from around…
Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification
Today’s episode of the VJHemOnc podcast focuses on the targeting of mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs) – a…
The impact of clinical signs & symptoms on outcomes in PV treated with hydroxyurea or ruxolitinib
Francesca Palandri, MD, PhD, University of Bologna, Bologna, Italy, highlights the prognostic relevance of the European Leukemia Net (ELN) clinical signs and symptoms in patients…
The use of venetoclax in advanced-stage R/R AL amyloidosis with cardiac involvement and t(11;14)
Max Rieger, MD, University Hospital Zurich, Zurich, Switzerland, discusses a study assessing the effectiveness of venetoclax in treating advanced-stage, relapsed/refractory (R/R) light chain (AL) amyloidosis…
Results of the SATISFY trial investigating mitapivat in erythrocyte membranopathies and CDA II
In this presentation, Thomas Doeven, MD, University Medical Center Utrecht, Utrecht, Netherlands, presents the primary results from the SATISFY trial (NCT05935202), a Phase II trial…
Considering patient-reported fatigue in MDS: a novel prognostic index
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, comments on the importance of incorporating patient-reported fatigue into the assessment of myelodysplastic…
Long-term outcomes of patients with Waldenström’s macroglobulinemia who discontinue BTKi therapy
Karan Chohan, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an analysis of the long-term outcomes of patients with Waldenström’s macroglobulinemia…